MedKoo Biosciences/CP-724714/200820/10mg

Synonym:CP724714;CP724714;CP-724714.

IUPAC/ChemicalName:(E)-2-methoxy-N-(3-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-6-yl)allyl)acetamide.

InChiKey:LLVZBTWPGQVVLW-SNAWJCMRSA-N

InChiCode:InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+

SMILESCode:O=C(NC/C=C/C1=CC2=C(NC3=CC=C(OC4=CC=C(C)N=C4)C(C)=C3)N=CN=C2C=C1)COC

TechnicalData

AdditionalInformation

References

1:FengB,XuJJ,BiYA,MirelesR,DavidsonR,DuignanDB,CampbellS,KostrubskyVE,DunnMC,SmithAR,WangHF.RoleofhepatictransportersinthedispositionandhepatotoxicityofaHER2tyrosinekinaseinhibitorCP-724,714.ToxicolSci.2009Apr;108(2):492-500.doi:10.1093/toxsci/kfp033.Epub2009Feb17.PubMedPMID:19223659.

2:JaniJP,FinnRS,CampbellM,ColemanKG,ConnellRD,CurrierN,EmersonEO,FloydE,HarrimanS,KathJC,MorrisJ,MoyerJD,PustilnikLR,RafidiK,RalstonS,RossiAM,SteynSJ,WagnerL,WinterSM,BhattacharyaSK.DiscoveryandpharmacologiccharacterizationofCP-724,714,aselectiveErbB2tyrosinekinaseinhibitor.CancerRes.2007Oct15;67(20):9887-93.PubMedPMID:17942920.

3:GuoF,LetrentSP,MunsterPN,BrittenCD,GelmonK,TolcherAW,SharmaA.PharmacokineticsofaHER2tyrosinekinaseinhibitorCP-724,714inpatientswithadvancedmalignantHER2positivesolidtumors:correlationswithclinicalcharacteristicsandsafety.CancerChemotherPharmacol.2008Jun;62(1):97-109.Epub2007Sep6.PubMedPMID:17805538.

4:MunsterPN,BrittenCD,MitaM,GelmonK,MintonSE,MoulderS,SlamonDJ,GuoF,LetrentSP,DenisL,TolcherAW.Firststudyofthesafety,tolerABIlity,andpharmacokineticsofCP-724,714inpatientswithadvancedmalignantsolidHER2-expressingtumors.ClinCancerRes.2007Feb15;13(4):1238-45.PubMedPMID:17317835.

5:GuoF,LetrentSP,SharmaA.PopulationpharmacokineticsofaHER2tyrosinekinaseinhibitorCP-724,714inpatientswithadvancedmalignantHER2positivesolidtumors.CancerChemotherPharmacol.2007Nov;60(6):799-809.Epub2007Feb7.PubMedPMID:17285315.